Receptor News and Research

RSS

High levels of gut bacterial toxin linked to increased lupus nephritis risk

The body's immune reaction to increased levels of a toxic molecule, part of a bacterial species in the human gut, may reveal who is most at risk of developing lupus nephritis, according to a new study led by NYU Langone Health.

23 Apr 2026

New antibody mechanism selectively suppresses harmful immune responses

The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens.

22 Apr 2026

Microglia actively shape glioblastoma growth and tumor spread

Glioblastoma, the most common and most aggressive brain tumor type in adults, remains difficult to treat because it can infiltrate surrounding brain tissue and spread far beyond the main tumor.

21 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

NHS grant funds study on the use of weight-loss drugs for treating PCOS

Dr. Shagaf Bakour, a gynecologist and director of medical education at Aston Medical School, has won an NHS research grant to investigate the use of weight-loss drugs in the treatment of polycystic ovary syndrome (PCOS).

21 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function.

20 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026

Researchers discover how cell membrane composition drives cancer proliferation

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment.

17 Apr 2026

Obesity, GLP-1s, and metabolic care

An interview with Professor Thomas Forst, Chief Medical Officer, hVIVO

From hVIVO 17 Apr 2026

Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global public health challenge with rapidly rising prevalence, especially in China. Despite advances in treatment, the underlying molecular mechanisms remain incompletely understood. A new research article published in the Chinese Medical Journal on March 16, 2026, provides critical insights into the role of exosomal microRNAs (miRNAs) in MASLD pathogenesis.

17 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

How the immune system may influence Alzheimer’s, Parkinson’s, and related diseases

This review argues that neurodegeneration is shaped not only by toxic protein buildup but also by immune signaling, with microglia and T cells able to either protect the brain or worsen damage depending on context. It also highlights aging, head injury, and viral infection as major forces that reshape CNS immunity and may influence disease progression and future treatment strategies.

16 Apr 2026

Researchers discover how stress signals weaken the aging immune system

As we age, our ability to maintain healthy blood and a strong immune system gradually declines, largely because hematopoietic stem cells (HSCs), the cells responsible for producing all blood cell types, begin to lose their effectiveness. Normally, HSCs can both self-renew and generate a balanced mix of blood cells, but over time they produce fewer new cells, favor certain cells such as myeloid cells over lymphoid cells, and struggle to support a robust immune response.

16 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).

From Bio-Rad Laboratories 15 Apr 2026

Study identifies new genes linked to severe pregnancy sickness

The USC research team that recently identified the hormone-encoding gene GDF15 as a key driver of pregnancy sickness has identified 9 additional genes linked to its most severe form, hyperemesis gravidarum (HG).

14 Apr 2026

SARS-CoV-2 rarely reaches first-trimester placentas but still disrupts early pregnancy immunity

Researchers analyzing 761 first-trimester pregnancies found that SARS-CoV-2 was rarely detected in placental tissues, suggesting in utero transmission early in pregnancy is uncommon. However, maternal infection was linked to immune dysregulation at the maternal-fetal interface, altered trophoblast signaling, and inflammatory changes that could affect placental development.

14 Apr 2026

Parents’ intake of sugar substitutes may influence offspring gut biology, study finds

A mouse study in Frontiers in Nutrition found that parental sucralose and stevia intake altered gut microbiota, short-chain fatty acids, and gene expression across generations, with sucralose showing the stronger and more persistent effects. The changes were transmitted to offspring not directly exposed to the sweeteners, although several effects were attenuated by the F2 generation.

13 Apr 2026

Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40 %, in adults in the UK.

From Bayer PLC 13 Apr 2026